Susceptibility of Contact Lens-Related
fractional inhibitory concentration
minimum bactericidal concentration
minimum inhibitory concentration
susceptibility
synergy
Journal
Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
20
09
2019
accepted:
29
12
2019
entrez:
22
8
2020
pubmed:
22
8
2020
medline:
22
8
2020
Statut:
epublish
Résumé
This study analyzed the susceptibilities of 17 contact lens (CL)-related keratitis isolates of Antibiotics included ciprofloxacin, levofloxacin, gentamicin, tobramycin, piperacillin, imipenem, ceftazidime, and polymyxin B. The MPDS OPTI-FREE PureMoist, Complete RevitaLens OcuTec, Biotrue, and Renu Advanced Formula and the constituent disinfectants; alexidine dihydrochloride, polyquaternium-1, polyaminopropyl biguanide, and myristamidopropyl dimethylamine (Aldox) were analyzed. The combined susceptibility of disinfectants based on the MPDS formulation was assessed through fractional inhibitory concentration. All isolates were susceptible to levofloxacin and gentamicin, 2/17 were resistant to ciprofloxacin; 1/17 was resistant to tobramycin, piperacillin, and polymyxin; and 3/17 were resistant to ceftazidime whereas 12/17 were resistant to imipenem. Of the four MPDSs, for Renu Advanced Formula 8/17 strains have an MIC ≤ 11.36 for OPTI-FREE PureMoist 14/17 strains have an MIC ≤ 11.36% for Complete RevitaLens 9/17 strains have an MIC ≤ 11.36, and for Biotrue 5/17 strains have MIC = 11.36. All strains were killed by 100% MPDS. At the concentrations used in the MPDSs, individual disinfectants were not active. From three tested isolates, no synergy was found in dual combinations of disinfectants. However, synergy was found for triple combination of disinfectants for three tested strains. Australian CL-related isolates of This study will help to choose better preventive and treatment measures for microbial keratitis.
Identifiants
pubmed: 32821474
doi: 10.1167/tvst.9.5.2
pii: TVST-19-1941
pmc: PMC7401903
doi:
Substances chimiques
Anti-Bacterial Agents
0
Disinfectants
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
2Informations de copyright
Copyright 2020 The Authors.
Déclaration de conflit d'intérêts
Disclosure: M. Khan, None; F. Stapleton, None; M.D.P. Willcox, None
Références
Eye Contact Lens. 2006 Dec;32(6):256-61
pubmed: 17099384
Antibiotics (Basel). 2018 Oct 15;7(4):
pubmed: 30326554
Exp Parasitol. 2017 Dec;183:187-193
pubmed: 28919333
Rev Sci Tech. 1995 Mar;14(1):57-74
pubmed: 7548972
Ophthalmology. 2006 Jan;113(1):109-16
pubmed: 16360210
Antimicrob Agents Chemother. 1983 Jan;23(1):142-50
pubmed: 6830204
PLoS One. 2015 Jun 11;10(6):e0126479
pubmed: 26067824
J Hosp Infect. 1999 Dec;43 Suppl:S57-68
pubmed: 10658759
Biochim Biophys Acta. 1984 Jan 11;769(1):57-66
pubmed: 6691980
Clin Microbiol Rev. 1999 Jan;12(1):147-79
pubmed: 9880479
Invest Ophthalmol Vis Sci. 2014 Dec 02;55(12):8475-9
pubmed: 25468893
J Antimicrob Chemother. 2006 Apr;57(4):764-6
pubmed: 16446373
Curr Eye Res. 2004 May;28(5):337-42
pubmed: 15287370
Clin Exp Optom. 2017 Jul;100(4):357-364
pubmed: 28194876
J Antimicrob Chemother. 2003 May;51(5):1153-8
pubmed: 12697638
Cornea. 2009 Sep;28(8):918-26
pubmed: 19654521
Antimicrob Agents Chemother. 2006 Jan;50(1):43-8
pubmed: 16377665
Antimicrob Agents Chemother. 2003 Jul;47(7):2093-9
pubmed: 12821452
Eye Contact Lens. 2015 May;41(3):177-82
pubmed: 25828515
Clin Exp Ophthalmol. 2019 Jan;47(1):20-25
pubmed: 30047184
Br J Ophthalmol. 2018 May;102(5):708-712
pubmed: 29459431
BMC Ophthalmol. 2014 Apr 24;14:54
pubmed: 24761794
Eye Contact Lens. 2018 Mar;44(2):125-131
pubmed: 27598555
Ann Clin Microbiol Antimicrob. 2014 Aug 20;13:41
pubmed: 25139679
Br J Ophthalmol. 2017 Feb;101(2):108-113
pubmed: 27130916
Antimicrob Agents Chemother. 1978 Nov;14(5):731-6
pubmed: 310281
Clin Exp Optom. 2018 Mar;101(2):162-171
pubmed: 29044738
J Antimicrob Chemother. 2003 Jul;52(1):1
pubmed: 12805255
Ophthalmology. 2005 Nov;112(11):1987
pubmed: 16183128
Ophthalmology. 2001 Oct;108(10):1826-9
pubmed: 11581056
Optom Vis Sci. 2005 Jun;82(6):446-50
pubmed: 15976580
Eye Contact Lens. 2016 May;42(3):158-62
pubmed: 26219076
J Clin Microbiol. 2001 Apr;39(4):1477-86
pubmed: 11283074
Biofouling. 2015;31(9-10):689-97
pubmed: 26469384
J Med Microbiol. 2008 Dec;57(Pt 12):1539-1546
pubmed: 19018027
Clin Exp Ophthalmol. 2007 Jul;35(5):421-6
pubmed: 17651246
J Antimicrob Chemother. 2010 Jun;65(6):1243-51
pubmed: 20375033
Optom Vis Sci. 2014 Mar;91(3):272-7
pubmed: 24509546
Ophthalmology. 2000 Aug;107(8):1497-502
pubmed: 10919897
BMC Ophthalmol. 2013 Oct 17;13:57
pubmed: 24134792
J Antimicrob Chemother. 2018 Jun 1;73(6):1724-1726
pubmed: 29547943
Antimicrob Agents Chemother. 1996 Aug;40(8):1914-8
pubmed: 8843303
Eye (Lond). 2012 Feb;26(2):327-30
pubmed: 22094301
Drug Resist Updat. 2000 Aug;3(4):247-255
pubmed: 11498392
Clin Infect Dis. 2002 Mar 1;34(5):634-40
pubmed: 11823954
Front Microbiol. 2014 Nov 26;5:643
pubmed: 25505462
Clin Exp Optom. 2013 Jan;96(1):58-64
pubmed: 22853742
Ophthalmology. 2008 Oct;115(10):1655-62
pubmed: 18538404
J Cataract Refract Surg. 2006 Mar;32(3):515-8
pubmed: 16631067
Cornea. 2008 Jan;27(1):22-7
pubmed: 18245962
Eye Contact Lens. 2015 Mar;41(2):91-7
pubmed: 25230082
Lancet Infect Dis. 2016 Feb;16(2):161-8
pubmed: 26603172